EGFR and glioblastoma: This antigen tends to have all of the appropriate antigenic properties for CAR-T therapy since it is one of the most frequent EGFR mutations in cancers but has no expression in normal tissues.63 Glioblastoma (GBM) is the fatal component in adult brain tumors, and GBM treatment does not improve life span.